October 31, 2012

Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine

--Additional data from Phase 2 studies to be presented at the American Heart Association’s Scientific Sessions 2012 --

 

Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
--Additional data from Phase 2 studies to be presented at the American Heart Association’s Scientific Sessions 2012 --

Paris, France and Tarrytown, N.Y., October 31, 2012 Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that results from a Phase 2 trial of SAR236553/REGN727 in patients with primary hypercholesterolemia were published in the October 31, 2012 issue of the New England Journal of Medicine.